| Name | Lincare |
|---|---|
| Organization Name | Lincare Inc |
| Location | 1566 Akron Peninsula Rd, Ste 2, Akron, Ohio 44313 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (330) 928-0884 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA.
Given the high stress levels, extended periods of screen time and regular social outings many Americans experience day-to-day in environments where high-calorie foods are readily available, it can be easy to fall into the habit of mindless eating - where we're too distracted to pay attention to how much, what and why we're eating. Research suggests that practicing mindfulness - or taking the time to bring awareness to present-moment experiences with an open attitude of curiosity and non-judgment - can be effective in allowing us to make more thoughtful food choices and recognize when we are hungry, satisfied or full.
Kaiser Health News provides a fresh take on health policy developments with "Rumpelstilt-Scare?" by Nate Beeler.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
Elsevier announced today the publication of two further important position statements from the European Menopause and Andropause Society in the journal Maturitas on common management problems in the post-reproductive health of women.
› Verified 7 days ago
| NPI Number | 1295899417 |
| Organization Name | LINCARE INC. |
| Doing Business As | LINCARE |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1566 Akron Peninsula Rd, Ste 2, Akron, OH 44313 |
| Phone Number | 330-928-0884 |
News Archive
While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA.
Given the high stress levels, extended periods of screen time and regular social outings many Americans experience day-to-day in environments where high-calorie foods are readily available, it can be easy to fall into the habit of mindless eating - where we're too distracted to pay attention to how much, what and why we're eating. Research suggests that practicing mindfulness - or taking the time to bring awareness to present-moment experiences with an open attitude of curiosity and non-judgment - can be effective in allowing us to make more thoughtful food choices and recognize when we are hungry, satisfied or full.
Kaiser Health News provides a fresh take on health policy developments with "Rumpelstilt-Scare?" by Nate Beeler.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
Elsevier announced today the publication of two further important position statements from the European Menopause and Andropause Society in the journal Maturitas on common management problems in the post-reproductive health of women.
› Verified 7 days ago
News Archive
While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA.
Given the high stress levels, extended periods of screen time and regular social outings many Americans experience day-to-day in environments where high-calorie foods are readily available, it can be easy to fall into the habit of mindless eating - where we're too distracted to pay attention to how much, what and why we're eating. Research suggests that practicing mindfulness - or taking the time to bring awareness to present-moment experiences with an open attitude of curiosity and non-judgment - can be effective in allowing us to make more thoughtful food choices and recognize when we are hungry, satisfied or full.
Kaiser Health News provides a fresh take on health policy developments with "Rumpelstilt-Scare?" by Nate Beeler.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
Elsevier announced today the publication of two further important position statements from the European Menopause and Andropause Society in the journal Maturitas on common management problems in the post-reproductive health of women.
› Verified 7 days ago
Rt Medical Services Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 730 W. Portage Trail Ext., Akron, Ohio 44313 Phone: (330) 920-9573 | |
Lincare Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1566 Akron Peninsula Rd, Akron, Ohio 44313 Phone: (330) 928-0884 | |
Giant Eagle Pharmacy # Type: Pharmacy Location: 484 E Waterloo Rd, Akron, Ohio 44319 Phone: (330) 773-7772 | |
Giant Eagle Pharmacy #4029 Type: Community/Retail Pharmacy Location: 2801 E Waterloo Rd, Akron, Ohio 44312 Phone: (330) 628-6067 | |
Cvs Pharmacy #04800 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 590e Market St, Akron, Ohio 44304 Phone: (330) 535-2700 |